Marc Bessler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marc Bessler has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
- Beth A. Schrope
Department of Surgery, Columbia University Irving Medical Center, New York, USA
2 shared publications - Abdus S. Wahed
Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York, USA
1 shared publication Abraham Krikhely
Division of Bariatric Surgery, Department of Surgery, Columbia University Irving Medical Center/New York-Presbyterian Hospital, New York, New York
1 shared publication- Abraham Krikhely
Division of Metabolic and Bariatric Surgery, Department of Surgery Columbia University Irving Medical Center New York New York USA
1 shared publication Akuenzunkpa Ude
1 shared publicationAkuezunkpa Ude
1 shared publication
Latest Publications
- Open Access
- 31 December 2024
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (1) , e70105
Rapid identification and phenotyping of nonalcoholic fatty liver disease patients using a machine‐based approach in diverse healthcare systems
Nonalcoholic fatty liver disease (NAFLD) is the most common global cause of chronic liver disease and remains under‐recognized within healthcare systems. Therapeutic interventions are rapidly advancing for its inflammatory phenotype, nonalcoholic steatohepatitis (NASH) at all stages of disease. Diagnosis codes alone fail to recognize and stratify at‐risk patients accurately. Our work aims to rapidly identify NAFLD patients within large electronic health record (EHR) databases for automated stratification and targeted intervention based on clinically relevant phenotypes. We present a rule‐based phenotyping algorithm for efficient identification of NAFLD patients developed using EHRs from 6.4 million patients at Columbia University Irving Medical Center (CUIMC) and validated at two independent healthcare centers. The algorithm uses the Observational Medical Outcomes Partnership (OMOP) Common Data Model and queries structured and unstructured data elements, including diagnosis codes, laboratory measurements, and radiology and pathology modalities. Our approach identified 16,006 CUIMC NAFLD patients, 10,753 (67%) previously unidentifiable by NAFLD diagnosis codes. Fibrosis scoring on patients without histology identified 943 subjects with scores indicative of advanced fibrosis (FIB‐4, APRI, NAFLD–FS). The algorithm was validated at two independent healthcare systems, University of Pennsylvania Health System (UPHS) and Vanderbilt Medical Center (VUMC), where 20,779 and 19,575 NAFLD patients were identified, respectively. Clinical chart review identified a high positive predictive value (PPV) across all healthcare systems: 91% at CUIMC, 75% at UPHS, and 85% at VUMC, and a sensitivity of 79.6%. Our rule‐based algorithm provides an accurate, automated approach for rapidly identifying, stratifying, and sub‐phenotyping NAFLD patients within a large EHR system.
- 31 December 2024
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (1) , e70105
Open AccessRapid identification and phenotyping of nonalcoholic fatty liver disease patients using a machine‐based approach in diverse healthcare systems
Nonalcoholic fatty liver disease (NAFLD) is the most common global cause of chronic liver disease and remains under‐recognized within healthcare systems. Therapeutic interventions are rapidly advancing for its inflammatory phenotype, nonalcoholic steatohepatitis (NASH) at all stages of disease. Diagnosis codes alone fail to recognize and stratify at‐risk patients accurately. Our work aims to rapidly identify NAFLD patients within large electronic health record (EHR) databases for automated stratification and targeted intervention based on clinically relevant phenotypes. We present a rule‐based phenotyping algorithm for efficient identification of NAFLD patients developed using EHRs from 6.4 million patients at Columbia University Irving Medical Center (CUIMC) and validated at two independent healthcare centers. The algorithm uses the Observational Medical Outcomes Partnership (OMOP) Common Data Model and queries structured and unstructured data elements, including diagnosis codes, laboratory measurements, and radiology and pathology modalities. Our approach identified 16,006 CUIMC NAFLD patients, 10,753 (67%) previously unidentifiable by NAFLD diagnosis codes. Fibrosis scoring on patients without histology identified 943 subjects with scores indicative of advanced fibrosis (FIB‐4, APRI, NAFLD–FS). The algorithm was validated at two independent healthcare systems, University of Pennsylvania Health System (UPHS) and Vanderbilt Medical Center (VUMC), where 20,779 and 19,575 NAFLD patients were identified, respectively. Clinical chart review identified a high positive predictive value (PPV) across all healthcare systems: 91% at CUIMC, 75% at UPHS, and 85% at VUMC, and a sensitivity of 79.6%. Our rule‐based algorithm provides an accurate, automated approach for rapidly identifying, stratifying, and sub‐phenotyping NAFLD patients within a large EHR system.
- 18 February 2024
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 20 (8) , 752-758
The financial toxicity of postbariatric body contouring surgery: a survey study of an urban tertiary care center’s patients
- 18 February 2024
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 20 (8) , 752-758
The financial toxicity of postbariatric body contouring surgery: a survey study of an urban tertiary care center’s patients
- Open Access
- 1 October 2021
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 17 (10) , 1787-1798
Postbariatric hypoglycemia: symptom patterns and associated risk factors in the Longitudinal Assessment of Bariatric Surgery study
- 1 October 2021
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 17 (10) , 1787-1798
Open AccessPostbariatric hypoglycemia: symptom patterns and associated risk factors in the Longitudinal Assessment of Bariatric Surgery study
- 27 March 2012
- Published by Wiley
- p. 320-332
Surgical Treatment of Severe Obesity: Patient Selection and Screening, Surgical Options, and Nutritional Management
- 27 March 2012
- Published by Wiley
- p. 320-332
Surgical Treatment of Severe Obesity: Patient Selection and Screening, Surgical Options, and Nutritional Management
- 1 May 1998
- Published by Springer Nature in Surgical Endoscopy
- Vol. 12 (5) , 436-439
An in vitro model fails to demonstrate aerosolization of tumor cells
Background: We investigated the ability of pressurized CO2 gas to aerosolize B16 melanoma (B16) tumor cells in an in vitro model. Methods: The experimental apparatus consisted of an 18.9-L plastic cylindrical vessel and a compliant latex pouch was attached to the top. Two 5-mm ports penetrated the vessel; insufflation and desufflation were carried out through them. A culture dish containing 20 million B16 cells in liquid culture media was placed at the base within the container. In the first experiment, the vessel was insufflated with CO2 gas to a static pressure of 15 or 30 mm Hg with the outflow port closed. After 10 min, the outflow port was opened and the gas was desufflated through a collecting device containing sterile culture medium. In a second experiment, a continuous flow of CO2 through the vessel was maintained after a pressure of 15 or 30 mm Hg was established. A total of 10 L CO2 was cycled through the vessel. In both experiments, 24 determinations were carried out at each pressure. Each experimental culture dish was microscopically scanned for 2 weeks for the presence of tumor cells. The third and fourth experiments tested for the presence of aerosolized nonviable tumor cells in the expelled gas. Using the model described above, after 10 mins of 30 mm Hg static pressure, the CO2 gas was expelled directly onto a glass slide and cytofixed. Alternately, after 10 mins at 30 mm Hg static pressure, the gas was expelled through a saline-filled Soluset (Abbott Laboratories), centrifuged, and the residue cytofixed onto a glass slide. Each of the five slides per experiment were examined microscopically for the presence of cells. Results: In the first and second experiments, no cells or growth were observed in any of the 96 experimental dishes. In experiments three and four, no cells were detected on any of the slides. Conclusions: It was not possible with this model to aerosolize tumor cells in a pressurized CO2 environment. Our results suggest that aerosolization of tumor cells is not the mechanism of port site recurrences after laparoscopic surgery for malignant disease.
- 1 May 1998
- Published by Springer Nature in Surgical Endoscopy
- Vol. 12 (5) , 436-439
An in vitro model fails to demonstrate aerosolization of tumor cells
Background: We investigated the ability of pressurized CO2 gas to aerosolize B16 melanoma (B16) tumor cells in an in vitro model. Methods: The experimental apparatus consisted of an 18.9-L plastic cylindrical vessel and a compliant latex pouch was attached to the top. Two 5-mm ports penetrated the vessel; insufflation and desufflation were carried out through them. A culture dish containing 20 million B16 cells in liquid culture media was placed at the base within the container. In the first experiment, the vessel was insufflated with CO2 gas to a static pressure of 15 or 30 mm Hg with the outflow port closed. After 10 min, the outflow port was opened and the gas was desufflated through a collecting device containing sterile culture medium. In a second experiment, a continuous flow of CO2 through the vessel was maintained after a pressure of 15 or 30 mm Hg was established. A total of 10 L CO2 was cycled through the vessel. In both experiments, 24 determinations were carried out at each pressure. Each experimental culture dish was microscopically scanned for 2 weeks for the presence of tumor cells. The third and fourth experiments tested for the presence of aerosolized nonviable tumor cells in the expelled gas. Using the model described above, after 10 mins of 30 mm Hg static pressure, the CO2 gas was expelled directly onto a glass slide and cytofixed. Alternately, after 10 mins at 30 mm Hg static pressure, the gas was expelled through a saline-filled Soluset (Abbott Laboratories), centrifuged, and the residue cytofixed onto a glass slide. Each of the five slides per experiment were examined microscopically for the presence of cells. Results: In the first and second experiments, no cells or growth were observed in any of the 96 experimental dishes. In experiments three and four, no cells were detected on any of the slides. Conclusions: It was not possible with this model to aerosolize tumor cells in a pressurized CO2 environment. Our results suggest that aerosolization of tumor cells is not the mechanism of port site recurrences after laparoscopic surgery for malignant disease.
- 1 January 1997
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 20 (3) , 340-345
Helium‐neon laser irradiation at fluences of 1, 2, and 4 J/cm2 failed to accelerate wound healing as assessed by both wound contracture rate and tensile strength
- 1 January 1997
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 20 (3) , 340-345
Helium‐neon laser irradiation at fluences of 1, 2, and 4 J/cm2 failed to accelerate wound healing as assessed by both wound contracture rate and tensile strength